BioSpace News Archive

Accuray Incorporated strengthened its Board of Directors with the appointment of James (Jim) M. Hindman, effective as of September 6, 2019, and expanding the company’s Board to nine members.

CUTERA®, INC. announced that Health Canada recently granted regulatory approval expanding the indications for use for truSculpt® iD to include reduction of circumference of the abdomen and non-invasive lipolysis.

Personalis, Inc., a leader in advanced genomics for cancer, announced that it has appointed Karin Eastham as an independent director to its Board of Directors.

Northwest Specialty Hospital recently opened Northwest Bone Health, an important new medical service that is the first of its kind in North Idaho.

Genomma Lab Internacional, S.A.B. de C.V. is pleased to announce that it has signed an exclusive license agreement with UP International, S. A. (“UPI”) to market the full range of infant nutrition products under the Novamil® and Novalac® brands in Mexico.

Discussion focused on powering digital transformation in healthcare

Nanotronics together with New York New York State Lieutenant Governor Kathy Hochul, announced that Nanotronics will open a high-tech manufacturing center at the Brooklyn Navy Yard, creating 190 new jobs and investing $11 million.

CANTEL MEDICAL CORP. (NYSE:CMD) will release the results for its fourth quarter ended July 31, 2019 on Monday, September 23, 2019 before the market opens, and hold a conference call to discuss the results at 8:30 a.m. ET.

*Seraphic Group, the fast-growing, future-thinking health and technology company on a mission to restore our planet’s natural cycles of human health and ecology, today announces that its best-selling RESTORE line of products that promote gut-brain health is now ION*Biome

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2019, which is the Company’s fourth quarter of fiscal year 2019 (“4Q19"